Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-10-11

Clinical Trial Update: Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity study of Saizen for adult growth hormone deficiency was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Saizen (somatropin)

Snippet

Sponsor: EMD Serono | Conditions: Growth Hormone Deficiency (GHD) | Phase 3 | Status: TERMINATED | Results posted: 2012-10-11